Buy Regenxbio Shares On Current Weakness

Shares of Regenxbio (NASDAQ:RGNX) have risen around 50% since my initial writeup on the company, in which I called it a speculative buy based on a high cash position, low valuation, widely adopted NAV technology platform, partnership with Biogen, and promising preclinical results in MPS I and MPS II.

RGNX Chart

RGNX data by YCharts

This early stage gene therapy pioneer story continues to evolve and I believe the investment thesis is strengthened.

READ FULL ARTICLE HERE